Lantheus Holdings, Inc. (FRA:0L8)

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
PYLARIFY Revenue	1.01B	1.06B	851.30M
PYLARIFY Revenue Growth	-4.06%	24.26%	61.41%
Other Radiopharmaceutical Oncology Revenue	-	384.00K	3.13M
Other Radiopharmaceutical Oncology Revenue Growth	-	-87.73%	-23.70%
Total Radiopharmaceutical Oncology Revenue	1.01B	1.06B	854.43M
Total Radiopharmaceutical Oncology Revenue Growth	-4.10%	23.85%	60.76%
DEFINITY Revenue	331.10M	317.79M	279.77M
DEFINITY Revenue Growth	4.19%	13.59%	14.19%
TechneLite Revenue	90.93M	95.49M	87.37M
TechneLite Revenue Growth	-4.78%	9.29%	-1.68%
Other Precision Diagnostics Revenue	24.86M	24.23M	22.98M
Other Precision Diagnostics Revenue Growth	2.61%	5.44%	0.68%
Total Precision Diagnostics Revenue	467.33M	437.51M	390.12M
Total Precision Diagnostics Revenue Growth	6.82%	12.15%	9.37%
Strategic Partnerships and Other Revenue	43.74M	38.18M	51.88M
Strategic Partnerships and Other Revenue Growth	14.55%	-26.40%	10.68%
Revenue (Total)	1.53B	1.53B	1.30B
Revenue (Total) Growth	-0.52%	18.32%	38.65%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Product Revenue	1.51B	1.52B	1.26B
Product Revenue Growth	-1.21%	20.72%	42.39%
License and Royalty Revenue	19.67M	9.13M	33.36M
License and Royalty Revenue Growth	115.48%	-72.64%	-30.53%
Revenue (Total)	1.53B	1.53B	1.30B
Revenue (Total) Growth	-0.52%	18.32%	38.65%

Updated Sep 30, 2025. Data Source: Fiscal.ai.